Reversing Cognitive Decline Advanced Clinical Training (ACT) in Treating Mild Cognitive Impairment (MCI) and Early Alzheimer's Disease (AD) 2017
In-Person Event
Dec 02 - 03, 2017
Miami Beach, Florida, USASpeakers
OVERVIEW
Reversing Cognitive Decline Advanced Clinical Training (ACT) in Treating Mild Cognitive Impairment (MCI) and Early Alzheimer's Disease (AD) is organized by Institute for Functional Medicine (IFM) and will be held during Dec 02 - 03, 2017 at Loews Miami Beach Hotel, Miami Beach, Florida, United States Of America.
The target audience for this medical event is Neurologists. This CME Conference has been approved for a maximum of 13.25 AMA PRA Category 1 Credits.
Course Description :
During this program, attendees will learn a multi-pronged treatment strategy for these patients. Using a systems biology approach, attendees will learn to assess patients for MCI and early AD, stratify them based on the likely causes of their dysfunction, and apply a multimodal protocol to individualize treatments for each patient that address the appropriate underlying causes. In this way, you can arrest cognitive decline and in many cases even reverse it.
Clinical Competencies :
• Recognize mild cognitive impairment and early dementia due to Alzheimer’s disease and differentiate these from other causes, including non-Alzheimer’s dementia.
• Evaluate the physiological underpinnings of MCI and early AD and the rationale for the systems approach to intervention that utilizes multimodal treatment strategies.
• Determine which of the six major subtypes of MCI/early AD that a patient has and select appropriate laboratory tests to evaluate the major contributors to each patient’s dysfunction.
• Explain the critical role of the collaborative care team approach in successfully treating MCI and early AD.
• Evaluate the importance of technological advances including neuroimaging, cognitive assessments, and therapeutic cognitive training in assessing and treating MCI and early AD.
Additional details will be posted as soon as they are available.
The target audience for this medical event is Neurologists. This CME Conference has been approved for a maximum of 13.25 AMA PRA Category 1 Credits.
Course Description :
During this program, attendees will learn a multi-pronged treatment strategy for these patients. Using a systems biology approach, attendees will learn to assess patients for MCI and early AD, stratify them based on the likely causes of their dysfunction, and apply a multimodal protocol to individualize treatments for each patient that address the appropriate underlying causes. In this way, you can arrest cognitive decline and in many cases even reverse it.
Clinical Competencies :
• Recognize mild cognitive impairment and early dementia due to Alzheimer’s disease and differentiate these from other causes, including non-Alzheimer’s dementia.
• Evaluate the physiological underpinnings of MCI and early AD and the rationale for the systems approach to intervention that utilizes multimodal treatment strategies.
• Determine which of the six major subtypes of MCI/early AD that a patient has and select appropriate laboratory tests to evaluate the major contributors to each patient’s dysfunction.
• Explain the critical role of the collaborative care team approach in successfully treating MCI and early AD.
• Evaluate the importance of technological advances including neuroimaging, cognitive assessments, and therapeutic cognitive training in assessing and treating MCI and early AD.
Additional details will be posted as soon as they are available.
KEY DATES
02 Dec, 2017
Event Start Date
03 Dec, 2017
Event End Date
SPECIALITIES
NeurologyPsychiatrySUGGESTED HOTELS
CONFERENCE VENUE
Loews Miami Beach HotelRELATED CONFERENCES & LIVE WEBINARS
Quick Links